Cyclosporine in severe childhood atopic dermatitis: A multicenter study
Cyclosporine in severe childhood atopic dermatitis: A multicenter study
复制标题
DOI：
10.1016/s0190-9622(96)90281-9
复制
发表时间：
1996-06-01
影响因子：
13.8
通讯作者：
GrahamBrown, RAC
中科院分区：
文献类型：
--
作者：
BerthJones, J;Finlay, AY;GrahamBrown, RAC
背景：严重特应性皮炎（AD）仍然难以治疗。环孢素对成人有效，但此前尚未在儿童 AD 中进行过研究。目的：目的是调查环孢素治疗严重难治性儿童 AD 的有效性、安全性和耐受性。方法：在一项开放研究中，2 至 16 岁的受试者接受环孢素治疗 6 周，每天 5 mg/kg。每两周通过体征评分、症状视觉模拟量表和生活质量调查问卷监测疾病活动度。监测不良事件。采用五点量表评估疗效和耐受性。结果：27 名儿童接受了治疗。所有疾病活动指标均出现显着改善。 22 例显示出明显改善或完全清除。儿童及其家人的生活质量得到改善。 25 名受试者的耐受性被认为是良好或非常好。结论：环孢素可能为患有严重 AD 的儿童提供有效、安全且耐受性良好的短期治疗选择。
Background: Severe atopic dermatitis (AD) remains difficult to treat. Cyclosporine is effecive in adults but has not previously been investigated in children with AD.Objective: The aims were to investigate the efficacy, safety, and tolerability of cyclosporine in severe refractory childhood AD.Methods: Subjects 2 to 16 years of age were treated for 6 weeks with cyclosporine, 5 mg/kg per day, in an open study. Disease activity was monitored every 2 weeks by means of sign scores, visual analogue scales for symptoms, and quality-of-life questionnaires. Adverse events were monitored. Efficacy and tolerability were assessed with five-point scales.Results: Twenty-seven children were treated. Significant improvements were seen in all measures of disease activity. Twenty-two showed marked improvement or total clearing. Quality of life improved for both the children and their families. Tolerability was considered good or very good in 25 subjects.Conclusion: Cyclosporine may offer an effective, safe, and well-tolerated short-term treatment option for children with severe AD.